Breast Cancer Trial Results
Zoledronic Acid Improves Early Breast Cancer Treatment
(Posted: 06/19/2008, Updated: 09/06/2011) - The addition of zoledronic acid (Zometa®) to adjuvant endocrine therapy in premenopausal women with early stage breast cancer significantly improves clinical outcomes beyond those achieved with endocrine therapy alone, according to findings presented at the 2008 ASCO meeting in Chicago.
Tool Weighs Benefits, Risks of Raloxifene or Tamoxifen to Prevent Breast Cancer
(Posted: 06/14/2011) - Researchers have developed a benefit-risk index to help guide decisions on whether postmenopausal women at increased risk of developing breast cancer should take raloxifene or tamoxifen to reduce that risk.
Eribulin Improves Survival of Women with Metastatic Breast Cancer
(Posted: 06/10/2011) - Treatment with eribulin (Halaven™) improved overall survival in women with metastatic breast cancer whose disease progressed despite multiple rounds of prior chemotherapy, according to the results of a phase III clinical trial called EMBRACE.
Five Years of Tamoxifen Continues to Benefit Women 15 Years after Treatment
(Posted: 06/03/2011) - In a large randomized clinical trial, women with early-stage breast cancer who received 5 years of adjuvant treatment with tamoxifen had better outcomes up to 15 years after the start of treatment than those who received 2 years of tamoxifen therapy.
Menopausal Estrogen Therapy Benefits and Risks Vary by Age, WHI Analysis Suggests
(Posted: 05/20/2011) - Long-term follow-up data from the Women’s Health Initiative (WHI) provide important new information about the potential risks and benefits of hormone therapy to treat symptoms or conditions related to menopause, including its effect on breast cancer risk, according to results published April 5, 2011, in the Journal of the American Medical Association.
(Posted: 06/19/2008, Updated: 09/06/2011) - The addition of zoledronic acid (Zometa®) to adjuvant endocrine therapy in premenopausal women with early stage breast cancer significantly improves clinical outcomes beyond those achieved with endocrine therapy alone, according to findings presented at the 2008 ASCO meeting in Chicago.
Tool Weighs Benefits, Risks of Raloxifene or Tamoxifen to Prevent Breast Cancer
(Posted: 06/14/2011) - Researchers have developed a benefit-risk index to help guide decisions on whether postmenopausal women at increased risk of developing breast cancer should take raloxifene or tamoxifen to reduce that risk.
Eribulin Improves Survival of Women with Metastatic Breast Cancer
(Posted: 06/10/2011) - Treatment with eribulin (Halaven™) improved overall survival in women with metastatic breast cancer whose disease progressed despite multiple rounds of prior chemotherapy, according to the results of a phase III clinical trial called EMBRACE.
Five Years of Tamoxifen Continues to Benefit Women 15 Years after Treatment
(Posted: 06/03/2011) - In a large randomized clinical trial, women with early-stage breast cancer who received 5 years of adjuvant treatment with tamoxifen had better outcomes up to 15 years after the start of treatment than those who received 2 years of tamoxifen therapy.
Menopausal Estrogen Therapy Benefits and Risks Vary by Age, WHI Analysis Suggests
(Posted: 05/20/2011) - Long-term follow-up data from the Women’s Health Initiative (WHI) provide important new information about the potential risks and benefits of hormone therapy to treat symptoms or conditions related to menopause, including its effect on breast cancer risk, according to results published April 5, 2011, in the Journal of the American Medical Association.
